Would Your Wound Care Biologics Documentation Survive an Audit

A patient comes in for a fourth biologic application. The chart shows a wound that measures larger than it did three visits ago, a photo from the first visit, and no note explaining why the plan has not changed. If a Medicare contractor pulled that record tomorrow, would the file defend the care?

The clinical case for advanced wound care biologics is real. Amniotic allografts, cellular and tissue-based products (CTPs), and other skin substitutes are a meaningful advance in treating chronic, non-healing wounds: conditions that cause enormous suffering, drive hospitalizations, and, in the most severe cases, lead to amputation. For the right patient at the right time, these products can be transformative.

That is precisely what makes their use so risky.

‍

Why Skin Substitutes Became an Enforcement Priority

Two forces put wound care biologics under the microscope. Spending surged: Medicare Part B spending on skin substitutes rose from $252 million in 2019 to over $10 billion in 2024, driven largely by payment rates and launch prices, according to CMS's CY 2026 fee schedule fact sheet.[1] Enforcement followed. In its June 2026 takedown announcement, the Department of Justice charged 11 defendants in connection with alleged amniotic allograft schemes. In one, it alleges that providers billed Medicare more than $4 billion for a single company's allografts between December 2021 and June 2024, resulting in more than $2 billion in payments.[2] These are allegations, and they center on kickbacks, medically unnecessary use, and, in some cases, products never provided.

Payment changed too. As of January 1, 2026, CMS pays most skin substitutes as incident-to supplies at a flat rate of roughly $127 per square centimeter, regardless of product.[3] That removes the incentive to favor higher-priced products, but not the scrutiny. Payment still scales with the area billed, so the pull to apply more product than a wound requires, or to apply a product when standard care would suffice, has not disappeared. The products are also easy to transport and apply in almost any setting, including mobile wound care operations, home visits, and nursing homes, which makes oversight difficult. Add the complexity of wound care documentation, and you face real regulatory and audit exposure.

‍

Why Wound Care Is Hard to Defend on Paper

Chronic wounds are difficult to photograph consistently, measurements vary, and healing trajectories are hard to predict. The provider is often a consultant focused only on the wound, not on the whole patient. Each of those gaps surfaces the moment a reviewer asks you to explain the record, and an outside reviewer works only from the record.

‍

What Does Medically Necessary Wound Biologic Use Look Like?

Medically necessary use means a documented wound, a documented failure of standard care, and a documented reason for every application that follows. The standard is not ambiguous. Too often, it is not followed when the financial incentive overrides clinical judgment. Strong documentation and revenue integrity practices make that standard visible in the record. Appropriate use requires clear, consistent documentation of:

• Wound etiology, such as trauma, diabetes, or vascular insufficiency
• Failure of standard wound care before a biologic begins, commonly four to six weeks of treatment
• Patient selection, including vascular status, nutritional status, infection, and the patient's willingness to take part in the plan of care
• Wound size (length, width, and depth), the assessment, and the amount of product applied and any amount discarded, with the rationale when sizing calls for an unusual amount of product
• Ongoing follow-up: the response to treatment, and whether continuing is justified when the response is inadequate

Coverage criteria vary by Medicare Administrative Contractor, so check what yours expects.

‍

Questions Leaders Should Be Asking

Copy these into an email and send them to your wound care leaders.

• Are we applying biologics to patients who have failed standard wound care, or are we skipping straight to the most reimbursable intervention?
• Are there patients receiving repeated biologic applications with no documented evidence of healing progress?
• Does the documentation include wound measurements, photographs, and a clear treatment history that an outside reviewer could follow?
• Are product sizes selected based on clinical need, and is the rationale documented?
• Are our wound care providers employed, contracted, or independent, and do we know what financial arrangements they have outside our organization?
• When did we last audit our wound care biologic use, and did that audit cover both coding accuracy and medical necessity?

Questions 5 and 6 are the best place to start. You can assess provider arrangements for fair market value, and confirm that pay does not rise with product volume, before an auditor does. You can also audit your wound care coding and medical necessity together, since a correctly coded claim can still lack a clinical rationale.

The best defense of legitimate use of wound-care biologics is more than a compliance program built to survive an audit. It is a clinical program built around the needs of real patients, carefully documented, rigorously monitored, and structured so that financial arrangements are irrelevant to the clinical decision. When the medicine drives the billing, the program is defensible.

We have worked alongside hospital and health system leaders for more than 35 years, and these are the questions worth answering before someone else asks them. If you would like a second set of eyes on your program, we are glad to talk it through.

Wound care biologics can be a legitimate, patient-centered therapy when the record tells the clinical story.

• Read our perspective on mitigating healthcare fraud
• See how our clinical medical necessity reviews put objective eyes on your wound care program
• Connect with our team to talk through where your program stands today